X4 Pharmaceuticals
BOSTON, MA · Founded 2010 · CIK 0001501697 · Biotech · Public
XOLREMDI (mavorixafor), a CXCR4 antagonist small molecule therapeutic for rare immune disorders
x4pharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $313M
- 10 Form D · Aug 2025
- 14 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $400,002 | |
| Private capital raised | Form D · SEC | $9,600,002 | |
| Private capital raised | Form D · SEC | $12,999,999 | |
| Private capital raised | Form D · SEC | $4,000,000 | |
| Private capital raised | Form D · SEC | $15,007,220 | |
| Private capital raised | Form D · SEC | $45,539,314 | |
| Private capital raised | Form D · SEC | $20,000,000 | |
| Private capital raised | Form D · SEC | $55,749,999 | |
| Private capital raised | Form D · SEC | $65,015,462 | |
| Private capital raised | Form D · SEC | $84,999,985 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2781 | Instil Bio, Inc. | — | $371M |
| 2782 | Legend Biotech Corp | — | $350M |
| 2783 | Sensei Biotherapeutics, Inc. | — | $349M |
| 2784 | X4 Pharmaceuticals | — | $313M |
| 2785 | Nuvation Bio | — | $275M |
| 2786 | CELL REPROGRAMMING & THERAPEUTICS LLC | — | — |
| 2787 | Veradermics | — | $269M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jan AdamsDirector
- William AliskiDirector
- Errik AndersonDirector · Executive Officer
- Christophe Arbet-EngelsExecutive Officer
- Mark BaldryExecutive Officer
- Robert BirnbaumExecutive Officer
- Gary BridgerDirector
- Dan BurgessDirector
- Daniel BurgessDirector
- Diego CadavidExecutive Officer
- William ClarkDirector
- Adam CraigDirector · Executive Officer
- Francoise de CraeckerDirector
- Francoise De CraeckerDirector
- Mary DiBiaseExecutive Officer
- Tillman GerngrossDirector · Executive Officer
- Carl GordonDirector
- Michael GrayExecutive Officer
- David KirskeExecutive Officer
- Alison LawtonDirector
- David MantusExecutive Officer
- David McGirrDirector
- Terrance McGuireDirector
- Derek MeisnerExecutive Officer
- Adam MostafaExecutive Officer
- Eszter NagyDirector · Executive Officer
- Claudio NessiDirector
- Paula RaganDirector · Executive Officer
- Michael RossDirector
- Rene RussoDirector · Executive Officer
- Amy SchulmanDirector
- Chris StevensExecutive Officer
- Murray StewartDirector · Executive Officer
- Arthur TaverasExecutive Officer
- John VolponeExecutive Officer
- Michael WyzgaDirector
Patents
- Methods For Treating Neutropeniagranted
- Treatments For Conditions Involving Increased IL-6 Levelsapplication
- Combination Therapies For Treating Hyperproliferative Disordersapplication
- Methods For Treating Neutropeniaapplication
- Dual CXCR4-BTK Inhibitorsapplication
- Methods For Treating Neutropeniagranted
- Synthesis Of Mavorixafor And Intermediates Thereofapplication
- Compositions Of CXCR4 Inhibitors And Methods Of Preparation And Useapplication
- Methods For Treating Immunodeficiency Diseaseapplication
- Methods For Treating Neutropeniagranted
- Methods For Treating Primary Immunodeficiencyapplication
- Compositions Of CXCR4 Inhibitors And Methods Of Preparation And Usegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.